Shaping the future health of babies
To ensure future mailings from SMA® Professional reach your mailbox, add smaprofessional@smaprofessional.msgfocus.com to your safe sender list.
View in browser
Shaping the future health of babies

Featured in this eNewsletter:

Your quick guide to human milk oligosaccharides (HMOs):
what they are and what they do


What research from ESPGHAN – Europe's biggest infant nutrition conference means for infant feeding

Introduction of New SMA® ADVANCED formulas: The 1st formula ranges in the UK and Ireland with HMOs

Dear [*data('salutation') || 'Healthcare Professional' *],

Welcome to the July edition of our eNewsletter, aimed to keep you updated with the latest news in infant nutrition.

This month we will be focusing on providing you with a quick guide to human milk oligosaccharides (HMOs) as well as an update from the ESPGHAN conference and what it means to infant nutrition. Also introducing New SMA® ADVANCED formula, the 1st formula range in UK & Ireland with HMOs.

Kind regards,
The SMA® Professional Team
What are HMOs and what do they do?

Human milk oligosaccharides (HMOs) are a hot topic in infant feeding. Research suggests that the reduced rate of infection and the more robust immune system of babies fed breast milk rather than infant formula may be due, in part, to HMOs.1-4

SMA® Nutrition has produced a handy guide to the unique role in breast milk of these complex carbohydrates, including the promising findings from a landmark trial of infant formula supplemented with HMOs.5
Find out more
Research identifies a possible mechanism for fewer respiratory infections associated with formula with 2 human milk oligosaccharides (HMOs)*

Nestlé scientists have found that HMOs support resistance to infection and boost protective effects of the gut wall that stop bacterial and viral pathogens getting into the blood.

A landmark clinical trial from 2017 with 88 babies fed a formula containing 2 HMOs* found that it is safe and well-tolerated, and supports age-appropriate growth; had significantly less bronchitis, fewer lower respiratory tract infection (LRTIs) and requirement for fewer antibiotics than 87 babies fed a formula without HMOs.5 Now this new research, presented at the annual meeting of the European Society for Paediatric Gastroenterology Hepatology and Nutrition(ESPGHAN), has found possible reasons why.

Effects of Infant Formula With Human Milk Oligosaccharides
on Growth and Morbidity


HMO-stimulated bifidobacteria contribute to risk reduction for LRTI with a 2-HMO containing infant formula through proactive effects on mucosal barrier function: Abstract N-P-178, page 1232
Find out more
The introduction of New SMA® Advanced formulas: The 1st formula range in UK & Ireland with HMOs

SMA® Nutrition, pioneers of research into HMOs for 30 years, has introduced the SMA® ADVANCED range to the UK and Ireland: first infant milk for babies 0–6 months, follow-on milk for those 6-12 months and growing up milk for older babies from 12–36 months. All three contain two HMOs* (2’FL and LNnT) not sourced from but structurally identical to those in breast milk, as well as 100% partially hydrolysed whey protein that is easier to digest. A study of an infant formula with the 2 HMOs* added found that it is safe and well-tolerated, and supports age-appropriate growth.5 In secondary outcomes there were significantly fewer lower respiratory tract infections, less bronchitis and fewer antibiotic prescriptions in HMO-formula infants compared with control.
Find out more
®Registered Trademark.

IMPORTANT NOTICE: The World Health Organisation (WHO) has recommended that pregnant women and new mothers be informed on the benefits and superiority of breastfeeding – in particular the fact that it provides the best nutrition and protection from illness for babies. Mothers should be given guidance on the preparation for, and maintenance of, lactation, with special emphasis on the importance of a well-balanced diet both during pregnancy and after delivery. Unnecessary introduction of partial bottle-feeding or other foods and drinks should be discouraged since it will have a negative effect on breastfeeding. Similarly, mothers should be warned of the difficulty of reversing a decision not to breastfeed. Before advising a mother to use an infant formula, she should be advised of the social and financial implications of her decision: for example, if a baby is exclusively bottle-fed, more than one can (400 g) per week will be needed, so the family circumstances and costs should be kept in mind. Mothers should be reminded that breast milk is not only the best, but also the most economical food for babies. If a decision to use an infant formula is taken, it is important to give instructions on correct preparation methods, emphasising that unboiled water, unsterilised bottles or incorrect dilution can all lead to illness. SMA® ADVANCED Follow-on Milk is only suitable for babies over 6 months as part of a mixed diet. It should not be used as a substitute for breast milk during the first 6 months of life. The decision to start weaning or to use this product before 6 months, should be made only on the advice of a doctor, midwife, health visitor, public health nurse, dietitian or pharmacist, based on baby’s individual needs. SMA® ADVANDED Growing Up Milk is suitable for young children from the 12th month, as part of a healthy balanced diet and it is not a breast milk substitute.

References
1. Kunz C. Historical aspects of human milk oligosaccharides. Adv Nutr 2012; 3(3): 430S–9S.
2. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 2012; 22(9): 1147–62.
3. Jantscher-Krenn E, Bode L. Human milk oligosaccharides and their potential benefits for the breast-fed neonate. Minerva Pediatr 2012; 64(1): 83–99.
4. Smilowitz JT, Lebrilla CB, Mills DA, et al. Breast milk oligosaccharides: structure-function relationships in the neonate. Annu Rev Nutr 2014; 34: 143–69.
5. Puccio G, Alliet P, Cajozzo C, et al. Effects of infant formula with human milk oligosaccharides on growth and morbidity: A randomized multicenter trial. J Pediatr Gastroenterol Nutr 2017; 64: 624–31.

To ensure future mailings from SMA® Professional reach your mailbox, add smaprofessional@smaprofessional.msgfocus.com to your safe sender list.

Contact SMA® Nutrition | Terms & conditions
This email is intended for residents of the UK
Unsubscribe

ZTC4530/06/19